RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > 2020 > 4 > Recon: GSK partners with Vir for COVID-19 treatments; Gilead to donate 1.5M doses of remdesivir

Recon: GSK partners with Vir for COVID-19 treatments; Gilead to donate 1.5M doses of remdesivir

Posted 06 April 2020 | By Michael Mezher 

Recon: GSK partners with Vir for COVID-19 treatments; Gilead to donate 1.5M doses of remdesivir

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
In Focus: US
  • US faces 'really bad' week as coronavirus deaths spike (Reuters) (NBC)
  • Inside the epic White House fight over hydroxychloroquine (Axios) (Reuters)
  • Pressed by Trump, US pushed unproven coronavirus treatment guidance (Reuters) (NYTimes) (The Guardian) (WSJ)
  • Trump says thousands of military to be sent to help states battle coronavirus (Reuters)
  • GSK to partner with Vir for potential COVID-19 treatments (Reuters) (STAT) (Endpoints) (Press)
  • Coronavirus patients rush to join studies of Gilead drug (AP)
  • Gilead ramps up production of remdesivir amid criticism over access, will donate 1.5 million doses (STAT) (Endpoints) (Press)
  • Biotech execs warn that the FDA is fumbling their response to the Covid-19 open-door promise, delaying progress (Endpoints)
  • Inovio coronavirus vaccine trial starts in Philadelphia, Kansas City (Business Insider) (Press)
  • FDA Commissioner Says China Not Creating Drug Shortages in US (Bloomberg)
  • Bet Big on Treatments for Coronavirus (WSJ)
  • Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer (STAT) (Endpoints)
  • Alnylam and Dicerna, onetime rivals, announce a ceasefire (STAT) (Endpoints)
  • Bristol Myers Squibb, Acceleron rack up second OK for Reblozyl, onto blockbuster status (Endpoints) (FDA) (Press)
In Focus: International
  • Greece suggests EU buy patent rights for vaccines and coronavirus tests: FAZ (Reuters)
  • WHO opens door to broader use of masks to limit spread of coronavirus (Reuters)
  • UK PM Johnson in hospital with persistent COVID-19 symptoms but still working (Reuters)
  • Japan to declare coronavirus emergency, launch stimulus of almost $1T (Reuters) (NPR)
  • Japan to boost Avigan drug stockpile as part of coronavirus stimulus (Reuters)
  • South Korea reports fewer than 50 new infections, earning WHO praise (Reuters)
  • Odd number in India coronavirus testing data sparks questions (Reuters)
  • India Bans All Exports of Virus Drug Often Touted by Trump (Bloomberg)
  • Covid-19 battle: Govt may Lift Hydroxychloroquine export ban (Economic Times) (Financial Times)
  • UK's Izana Bioscience tests rheumatoid arthritis drug in COVID-19 patients (Reuters)
  • Lilly Asia Ventures co-leads $100M+ round for Chinese biotech and its late-stage lupus drug (Endpoints)
  • Servier snaps up antibody biotech Symphogen, looks to become 'recognized oncology player' (Fierce) (PMLive)
Coronavirus Outbreak
  • COVID-19 Vaccines: Ex-FDA Leaders Urge High Bar For Emergency Use Authorization (Pink Sheet-$)
  • 430,000 People Have Traveled From China to US Since Coronavirus Surfaced (NYTimes)
  • Democratic Health Leaders Call For Free Covid-19 Treatment For All Americans (Senate Ways and Means)
  • FDA commissioner Hahn: We have been working on convalescent plasma treatment (Fox)
  • FDA: No evidence COVID-19 can be transmitted by food or packaging on food (Roll Call)
  • US coronavirus supply spree sparks outrage among allies (Reuters)
  • How sewage could reveal true scale of coronavirus outbreak (Nature)
  • Tiger at New York's Bronx Zoo tests positive for coronavirus (Reuters)
  • The ‘certified recovered’ from Covid-19 could lead the economic recovery (STAT)
  • CVS ramps up drive-through coronavirus testing sites with faster kits (Reuters)
  • Could TB vaccine protect medics from COVID-19? (France24)
  • Mysterious Heart Damage, Not Just Lung Troubles, Befalling COVID-19 Patients (KHN)
  • ‘You Pray That You Got The Drug.’ Ailing Couple Gambles On Trial For COVID-19 Cure (KHN)
  • Early Data Shows African Americans Have Contracted and Died of Coronavirus at an Alarming Rate (ProPublica)
  • Does Covid-19 Hit Women and Men Differently? U.S. Isn’t Keeping Track (NYTimes)
  • Along the Border, the Population Is High Risk for Coronavirus, but Testing Is In Short Supply (ProPublica)
  • This tiny federal agency was built to respond to a crisis like coronavirus. Now that it’s here, is BARDA ready? (STAT)
  • New York governor sees 'return to normalcy' with rapid coronavirus testing (Reuters)
  • Getinge to ramp up ventilator production capacity by 160% due to coronavirus (Reuters)
  • Tesla engineers show ventilator prototype on YouTube (Reuters)
  • Key Issues As Automakers Shift To Medical Device Production (Law360)
  • CDC launches studies to get more precise count of undetected Covid-19 cases (STAT)
  • An interview with the CDC director on coronavirus, masks, and an agency gone quiet (STAT)
  • Inside a major coronavirus vaccine effort that hopes to start early production to meet demand (NBC)
  • Amazon in contact with coronavirus test makers for potential screenings on employees (Reuters)
  • China Pushes for Quiet Burials as Coronavirus Death Toll Is Questioned (NYTimes)
  • China sees rise in asymptomatic coronavirus cases, to tighten controls at land borders (Reuters)
  • Japan animal ventilator maker looks to boost output for human coronavirus patients (Reuters)
  • Queen Elizabeth II Addresses U.K. In Rare Televised Speech About The Coronavirus (NPR)
  • UK ramps up coronavirus trials but results 'a few months away' (Reuters)
  • Miracle cures? UK investigators go after fake coronavirus medicines (Reuters) (MHRA)
  • Britain secures 300 new ventilators from China (Reuters)
  • NICE publishes new COVID-19 management guidelines (PMLive)
  • Novacyt wins French approval for COVID testing kit (Reuters)
  • Italy starts to look ahead to 'phase two' as COVID-19 death toll slows (Reuters)
  • Italy experts say reliable coronavirus antibody test may be ready soon (Reuters)
  • Germany ‘is still at the beginning of the epidemic’ despite low death rate, health body warns (CNBC)
  • Swiss face shortage of ethanol for disinfectant after abandoning stockpile (Reuters)
  • Finland, ‘Prepper Nation of the Nordics,’ Isn’t Worried About Masks (NYTimes)
  • Ontario lab design left province short of coronavirus testing supplies (Reuters)
  • Canada's Ontario warns coronavirus cases will soar without further distancing measures (Reuters)
  • Russia's coronavirus cases jump by almost 1,000 in 24 hours (Reuters)
  • "They just sedate them"; coronavirus overwhelms Spain's care homes (Reuters)
  • Wockhardt Hospital in Mumbai unwittingly becomes a Covid hot zone after many staffers test positive (Economic Times)
  • 23andMe Engages Its Millions of Research Participants to Study COVID-19 (Press)
  • Hope Biosciences Receives FDA Approval to Commence First Stem Cell Clinical Trial for Protection Against COVID-19 (Press)
  • OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12, an Investigational Vaccine to Prevent COVID-19, Combining an Enhanced "Spike" DNA Sequence and TAVO (Press)
Pharmaceuticals & Biotechnology
  • Another day, another boatload for biotech. Deerfield adds $840M to rush of venture dollars (Endpoints)
  • Small molecules, biologics and now gene therapies: Germany's Evotec adds another feather to its R&D cap (Endpoints)
  • Gilead to lean on Second Genome's microbiome work in $38M research pact (BioPharmaDive)
  • Next-generation stem cells — ushering in a new era of cell-based therapies (Nature)
  • The 20 under 40: Inside the next generation of biopharma leaders (Endpoints)
  • Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies (Xconomy)
  • Individualized Therapeutics Could Get Boost From NIH Platform Gene Therapy Pilot (Pink Sheet-$)
  • Pfizer signs up for longer pact with Icon, pens extra 2-year clause (Fierce)
  • Alkermes clinical lead jumps ship to slimmed-down, refocused Seres (Fierce)
  • Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act (FDA)
Pharmaceutical & Biotechnology: Study Results, Filings & Designations
  • A pair of PhIII failures spells last rites for Menlo’s once-promising Merck drug (Endpoints)
  • Axsome celebrates migraine PhIII win, shifting eyes toward a pair of Q4 submissions (Endpoints)
  • LFB Announces FDA Approval of SEVENFACT®, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors (Press)
  • The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, in Psoriatic Arthritis (Press)
  • Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium (Press)
  • OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact® in Patients With Primary Hyperoxaluria (Press)
  • Millendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide in Patients with Prader-Willi Syndrome (PWS) (Press)
Medical Devices
  • Updated Letter to Industry on COVID-19 (FDA)
  • Axonics® Submits PMA Supplement to U.S. Food & Drug Administration to Expand Full-Body MRI Labeling for 3T Scans (Press)
  • Aptar Requests US FDA Emergency Use Authorization for N95 Filtering Facepiece Respirator Decontamination with ActivShieldTM (Press)
US: Assorted & Government
  • Obamacare's health care protections face first true test in coronavirus crisis (NBC)
  • Supreme Court Postpones April Argument Session (Law360)
  • More Bad Comment k Law from the Eastern District of Pennsylvania (Drug & Device Law)
  • Boehringer Ingelheim Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2020) (Patent Docs)
  • FSIS Admits Its Policy for Product of USA Labeling is Misleading; Will Undertake Rulemaking (FDA Law Blog)
  • The MDR amendment proposal: more than meets the eye (MedicalDevicesLegal)
  • EMA Set To Discuss Safety Of Ranitidine Drugs Soon (Pink Sheet-$)
  • Medicines: get scientific advice from MHRA (MHRA)
  • China restarts drug despatches, India's curbs hold them in transit (Economic Times)
  • Indian pharma companies secure 336 ANDA approvals from US FDA during 2019 (Pharmabiz)
  • Lupin launches generic drug used for prevention of organ rejection in kidney transplant in US (Economic Times)
  • India’s regulator looks to relax clinical trial protocols in face of COVID-19 challenge (Pharmaletter-$)
  • Amendments to the new restrictions on prescribing hydroxychloroquine for COVID-19 (TGA)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
Need to contact the editor of Regulatory Reconnaissance? Email us at news@raps.org.
A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.